CAS 357336-20-0 Brivaracetam White Crystalline Powder 99.5% Purity

Basic Information
Place of Origin: China
Brand Name: Senwayer Brand
Certification: ISO, 9001, USP
Model Number: 357336-20-0
Minimum Order Quantity: 10grams
Price: Negotiation
Packaging Details: 10g, 20g, 50g , 100g, 500g. 1kg, 10kg
Delivery Time: within 2 working days
Payment Terms: T/T in advance, Money Gram, Western Union, Bank Transfer.
Supply Ability: 1000kg/month
Detail Information
CAS: 357336-20-0 Apparence: Almost White Crystalline Powder
Purity: 99.5% Main Usage: Brain Health Drug
Grade: Pharma Grade Stock: Enough Stock
High Light:

pharmaceutical raw chemical


api raw material

Product Description

Brivaracetam Briviact CAS 357336-20-0 Active Pharmaceutical Ingredients​ Powder


Quick detail

Product Name :  Brivaracetam ; (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;UCB-34714
CAS No.  357336-20-0
Molecular Formula  C11H20N2O2
Molecular Weight  212.29
Assay  99%
Appearance White off-white crystalline powder
Grade Standard Medicine Grade
Appearance White crystal or crystalline powder
Storage Store in well-closed container, protec...


Brivaracetam  Description

The precise mechanism by which brivaracetam exerts its antiepileptic activity is unknown. Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the antiepileptic effect.


Brivaracetam is a prescription medication used with other medicines to treat partial-onset seizures in people 16 years of age and older with epilepsy. Brivaracetam belongs to a group of drugs called antiepileptics. These work by reducing the frequency of seizures.


This medication comes in a tablet and solution form and is usually taken 2 times a day by mouth with or without food. The brivaracetam tablets should be swallowed whole with liquid. Do not crush or chew brivaracetam tablets before swallowing.


This medication is also available in an injectable form to be given directly into a vein (IV) by a healthcare professional.


Brivaracetam Dosage

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.


Solution, Intravenous:

Briviact: 50 mg/5 mL (5 mL)

Solution, Oral:

Briviact: 10 mg/mL (300 mL) [contains methylparaben; raspberry flavor]

Tablet, Oral:

Briviact: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg

Half-Life Elimination  About~9 hours

Protein Binding   ≤20% to plasma proteins


Brivaracetam Dosing: Adult

Partial onset seizures: Oral, IV: Initial: 50 mg twice daily; may decrease to 25 mg twice daily or increase up to 100 mg twice daily based on individual patient response and tolerability (maximum: 200 mg/day). Note: Use injection when oral administration is temporarily not feasible; clinical study experience with brivaracetam injection is limited to 4 consecutive days of treatment.

Dosage adjustment for concomitant therapy with rifampin: Increase brivaracetam dosage by up to 100% (ie, double the brivaracetam dose).

Discontinuation of therapy: Reduce gradually; it has been recommended to reduce the dose by 50 mg/day on a weekly basis with the final week of treatment at the dose of 20 mg/day (Brivlera Canadian product labeling 2016).


Dosing: Geriatric

Refer to adult dosing. Consider starting at the low end of the dosage range.

Dosing: Pediatric

Partial onset seizures: Adolescents ≥16 years: Oral, IV: Refer to adult dosing.

Dosing: Renal Impairment

Mild to severe impairment: No dosage adjustment necessary.

End-stage renal disease requiring dialysis: Use is not recommended (has not been studied).

Dosing: Hepatic Impairment

Mild to severe impairment (Child Pugh classes A, B, and C): Initial: 25 mg twice daily, up to a maximum of 75 mg twice daily.


Brivaracetam Administration

Injection: Administer IV over 2 to 15 minutes; may administer undiluted or diluted with NS, LR, or D5W.

Oral solution: Administer with or without food. Use a calibrated measuring device to measure (household teaspoon or tablespoon is not an adequate measuring device). May also be administered using a nasogastric tube or gastronomy tube.

Tablets: Administer with or without food. Swallow tablets whole with liquid; do not chew or crush.


How to take and store Brivaracetam?

Taking medicine: It's important to take any seizure medication the same way every day.

  • When a medicine is taken twice a day, try to take it the same times each day - usually morning and night about 12 hours apart.
  • Briviact can be taken with or without food.

Using tablets:

  • Should be taken whole with a liquid.
  • Do not chew or crush the tablets.

Using the oral solution:

  • Use an accurate measuring device instead of a teaspoon to measure how much to take.
  • Do not dilute the solution.
  • This can be given thru a nasogastric (NG) tube or a gastrostomy tube (G tube) in people who are not able to take oral foods or medicines.

Remembering medicine: Since missing doses of seizure medications can lead to breakthrough seizures, use reminders to help you avoid missing doses. Examples of reminders may include:

  • Time the medicines to something you do at the same time each day, for example after eating a meal or brushing teeth
  • Use a pillbox, daily or weekly
  • Set alarms on phones, clocks, or other electronic devices
  • Have reminder alerts, emails, or texts sent to an electronic device by a seizure diary

Storing medicine:

  • Keep the medicine at 25°C (77°F) or between 15°C to 30°C (59°F to 86°F).
  • Throw away any unused Briviact oral solution 5 months after the bottle was first opened.
  • The vial of medicine for the injection form is intended to be used only once. Do not save any unused open drug for the injection form.

Brivaracetam Adverse Reactions

Frequency not always defined.

Central nervous system: Fatigue (≤20% to ≤27%; dose-dependent), hypersomnia (≤20% to ≤27%; dose-dependent), lethargy (≤20% to ≤27%), malaise (≤20% to ≤27%; dose-dependent), drowsiness (≤16% to ≤27%; dose-dependent), sedation (≤16% to ≤27%; dose-dependent), dizziness (12% to ≤16%), equilibrium disturbance (≤3% to ≤16%), abnormal gait (≤16%), ataxia (≤16%), vertigo (≤16%), psychiatric disturbance (13%; includes psychotic and nonpsychotic), euphoria (IV: ≥3%), feeling drunk (IV: ≥3%), infusion-site pain (IV: ≥3%), irritability (3%), suicidal ideation

Gastrointestinal: Nausea and vomiting (5%), dysgeusia (IV:≥3%), constipation (2%)

Hematologic & oncologic: Decreased white blood cell count (2%)

Hypersensitivity: Hypersensitivity reaction

Neuromuscular & skeletal: Weakness (≤20% to ≤27%)

Ophthalmic: Nystagmus (≤16%)

<1% (Limited to important or life-threatening): Angioedema, bronchospasm, decreased neutrophils



Contact Details
Abby Xiang

Phone Number : +8617764031156

WhatsApp : +8617764031156